dict.md logo
Results for E in English, page 67
END STAGE RENAL DISEASE (ESRD) RELATED SERVICES DURING THE COURSE OF TREATMENT, FOR PATIENTS BETWEEN 12 AND 19 YEARS OF AGE TO INCLUDE MONITORING FOR THE ADEQUACY OF NUTRITION, ASSESSMENT OF GROWTH AND DEVELOPMENT, AND COUNSELING OF PARENTS; WITH 2 OR 3 F
END STAGE RENAL DISEASE (ESRD) RELATED SERVICES DURING THE COURSE OF TREATMENT, FOR PATIENTS BETWEEN 2 AND 11 YEARS OF AGE TO INCLUDE MONITORING FOR THE ADEQUACY OF NUTRITION, ASSESSMENT OF GROWTH AND DEVELOPMENT, AND COUNSELING OF PARENTS; WITH 1 FACE-TO
END STAGE RENAL DISEASE (ESRD) RELATED SERVICES DURING THE COURSE OF TREATMENT, FOR PATIENTS BETWEEN 2 AND 11 YEARS OF AGE TO INCLUDE MONITORING FOR THE ADEQUACY OF NUTRITION, ASSESSMENT OF GROWTH AND DEVELOPMENT, AND COUNSELING OF PARENTS; WITH 2 OR 3 FA
END STAGE RENAL DISEASE (ESRD) RELATED SERVICES DURING THE COURSE OF TREATMENT, FOR PATIENTS BETWEEN 2 AND 11 YEARS OF AGE TO INCLUDE MONITORING FOR THE ADEQUACY OF NUTRITION, ASSESSMENT OF GROWTH AND DEVELOPMENT, AND COUNSELING OF PARENTS; WITH 4 OR MORE
END STAGE RENAL DISEASE (ESRD) RELATED SERVICES DURING THE COURSE OF TREATMENT, FOR PATIENTS UNDER 2 YEARS OF AGE TO INCLUDE MONITORING FOR THE ADEQUACY OF NUTRITION, ASSESSMENT OF GROWTH AND DEVELOPMENT, AND COUNSELING OF PARENTS; WITH 1 FACE-TO-FACE PHY
END STAGE RENAL DISEASE (ESRD) RELATED SERVICES DURING THE COURSE OF TREATMENT, FOR PATIENTS UNDER 2 YEARS OF AGE TO INCLUDE MONITORING FOR THE ADEQUACY OF NUTRITION, ASSESSMENT OF GROWTH AND DEVELOPMENT, AND COUNSELING OF PARENTS; WITH 4 OR MORE FACE-TO-
END STAGE RENAL DISEASE (ESRD) RELATED SERVICES FOR HOME DIALYSIS PATIENTS PER FULL MONTH; FOR PATIENTS TWELVE TO NINETEEN YEARS OF AGE TO INCLUDE MONITORING FOR ADEQUACY OF NUTRITION, ASSESSMENT OF GROWTH AND DEVELOPMENT, AND COUNSELING OF PARENTS
END STAGE RENAL DISEASE (ESRD) RELATED SERVICES FOR HOME DIALYSIS PATIENTS PER FULL MONTH; FOR PATIENTS TWENTY YEARS OF AGE AND OLDER
END STAGE RENAL DISEASE (ESRD) RELATED SERVICES FOR HOME DIALYSIS PATIENTS PER FULL MONTH; FOR PATIENTS TWO TO ELEVEN YEARS OF AGE TO INCLUDE MONITORING FOR ADEQUACY OF NUTRITION, ASSESSMENT OF GROWTH AND DEVELOPMENT, AND COUNSELING OF PARENTS
END STAGE RENAL DISEASE (ESRD) RELATED SERVICES FOR HOME DIALYSIS PATIENTS PER FULL MONTH; FOR PATIENTS UNDER TWO YEARS OF AGE TO INCLUDE MONITORING FOR ADEQUACY OF NUTRITION, ASSESSMENT OF GROWTH AND DEVELOPMENT, AND COUNSELING OF PARENTS
END STAGE RENAL DISEASE (ESRD) RELATED SERVICES LESS THAN FULL MONTH, PER DAY; FOR PATIENTS BETWEEN TWELVE AND NINETEEN YEARS OF AGE
END STAGE RENAL DISEASE (ESRD) RELATED SERVICES LESS THAN FULL MONTH, PER DAY; FOR PATIENTS BETWEEN TWO AND ELEVEN YEARS OF AGE
END STAGE RENAL DISEASE (ESRD) RELATED SERVICES LESS THAN FULL MONTH, PER DAY; FOR PATIENTS TWENTY YEARS OF AGE AND OVER
END STAGE RENAL DISEASE (ESRD) RELATED SERVICES LESS THAN FULL MONTH, PER DAY; FOR PATIENTS UNDER TWO YEARS OF AGE
END STAGE RENAL DISEASE (ESRD) RELATED SERVICES, DURING THE COURSE OF TREATMENT, FOR PATIENTS BETWEEN 12 AND 19 YEARS OF AGE TO INCLUDE MONITORING FOR THE ADEQUACY OF NUTRITION, ASSESSMENT OF GROWTH AND DEVELOPMENT, AND COUNSELING OF PARENTS; WITH 4 OR MO
END STAGE RENAL DISEASE PATIENT REQUIRING HEMODIALYSIS DOCUMENTED TO HAVE RECEIVED VASCULAR ACCESS OTHER THAN AUTOGENOUS AV FISTULA
END STAGE RENAL DISEASE PATIENT REQUIRING HEMODIALYSIS VASCULAR ACCESS DOCUMENTED TO HAVE RECEIVED AUTOGENOUS AV FISTULA
END STAGE RENAL DISEASE PATIENT WITH DOCUMENTED DIALYSIS DOSE OF URR GREATER THAN OR EQUAL TO 65% (OR KT/V GREATER THAN OR EQUAL TO 1.2)
END STAGE RENAL DISEASE PATIENT WITH DOCUMENTED DIALYSIS DOSE OF URR LESS THAN 65% (OR KT/V LESS THAN 1.2)
END STAGE RENAL DISEASE PATIENT WITH DOCUMENTED HEMATOCRIT GREATER THAN OR EQUAL TO 33 (OR HEMOGLOBIN GREATER THAN OR EQUAL TO 11)
END STAGE RENAL DISEASE PATIENT WITH DOCUMENTED HEMATOCRIT LESS THAN 33 (OR HEMOGLOBIN LESS THAN 11)
End stage renal failure
End state
end stiffener
end stop
end stops
End systolic
End systolic | Heart Ventricle Left
End systolic | Heart Ventricle Right
End systolic | Heart.ventricle Right
End systolic blood pressure by US
End systolic:Vol:Pt:Heart.ventricle.left:Qn:Imaging
End systolic:Vol:Pt:Heart.ventricle.right:Qn:Imaging
End systolic:Volume:Point in time:Heart.ventricle.left:Quantitative:Imaging
End systolic:Volume:Point in time:Heart.ventricle.right:Quantitative:Imaging
end terminal
end terminals
end tie plate
end tie plates
End Time
end to end
End Too Late Alert
End Too Late Alert - ActCode
end up
end user
end user licence agreement /EULA/
end users
end vise
end wall
END-1 protein, C elegans
END-3 protein, C elegans
END-BINDING PROTEIN 1
end-binding protein 3, human
End-Cut Biopsy Guns
End-Diastolic Compression Units
End-Diastolic Volume, Ventricular
End-Diastolic Volumes, Ventricular
End-Expiratory Pressure, Positive
End-Expiratory Pressures, Positive
end-group
end-of-address character
end-of-course dance
end-of-course tournament
End-of-life care
End-of-life Nursing
End-of-Life Treatment Management
end-of-life vehicle
end-of-the-line
end-of-the-year review
end-on view
End-plate irregularities
End-Plate, Motor
End-Plates, Motor
End-Point
End-Point Titration, Skin
End-Point Titrations, Skin
End-Position Nystagmus
end-rhyme
end-rhymes
End-stage
End-Stage disease, 6 or fewer months to live
End-Stage disease, 6 or fewer months to live | patient
End-Stage disease, 6 or fewer months to live | patient | Bld-Ser-Plas
end-stage glomerulonephritis chronic
End-Stage Kidney Disease
End-stage liver disease before adulthood
End-stage renal disease
End-stage renal disease (ESRD) related services (less than full month), per day; for patients twenty years of age and older
End-stage renal disease (ESRD) related services (less than full month), per day; for patients younger than two years of age
End-stage renal disease (ESRD) related services per full month; for patients between twelve and nineteen years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents
End-stage renal disease (ESRD) related services per full month; for patients between two and eleven years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents
End-stage renal disease (ESRD) related services per full month; for patients twenty years of age and older
End-stage renal disease (ESRD) related services per full month; for patients younger than two years of age to include monitoring for the adequacy of nutrition, assessment of growth and development, and counseling of parents
End-Stage Renal Disease (ESRD) Treatment
End-Stage Renal Disease (ESRD) Treatment - NUCCProviderCodes
End-stage renal disease develops in childhood
END-STAGE RENAL DISEASE PATIENT REQUIRING HEMODIALYSIS VASCULAR ACCESS WAS NOT AN ELIGIBLE CANDIDATE FOR AUTOGENOUS AV FISTULA
END-STAGE RENAL DISEASE PATIENT WITH A HEMATOCRIT OR HEMOGLOBIN NOT DOCUMENTED
END-STAGE RENAL DISEASE PATIENT WITH URR OR KT/V VALUE NOT DOCUMENTED, BUT OTHERWISE ELIGIBLE FOR MEASURE
End-Stage Renal Disease Services
END-STAGE RENAL DISEASE, DIABETIC, SUSCEPTIBILITY TO
END-STAGE RENAL DISEASE, DIABETIC, SUSCEPTIBILITY TO (finding)
END-STAGE RENAL DISEASE, NONDIABETIC, SUSCEPTIBILITY TO
End-Stage Renal Failure
End-Systolic Volume, Ventricular
End-Systolic Volumes, Ventricular
End-Tidal Carbon Dioxide Detectors
End-Tidal Carbon Dioxide Esophageal Intubation Detectors
End-Tidal Carbon Dioxide Measuring Devices
end-to-end
End-to-Side Anastomosis
end-user
end-users
end|ends
END1 protein, S cerevisiae
END3 protein, S cerevisiae
END4 protein, E coli
End4 protein, S pombe
End5 protein, S cerevisiae
END6 protein, S cerevisiae
END7 protein, S cerevisiae
END8 protein, S cerevisiae
endA protein, bacteria
Endabuse
Endacof AC
Endacof AC Oral Solution
Endacof HC
Endacof HC 2/1.7/30 per 5 ML Oral Solution
Endacof HC, 2 mg-1.7 mg-30 mg/5 mL oral liquid
Endacof PD
Endacof PD (brompheniramine 1 MG / dextromethorphan 3 MG / pseudoephedrine 12.5 MG) per ML Oral Solution
Endacof XP
Endacof XP 2.5/200 (hydrocodone / guaifenesin) per 5 ML Syrup
Endacof XP, 200 mg-2.5 mg/5 mL oral liquid
EndaCof-AC
EndaCof-AC, 2 mg-10 mg/5 mL oral syrup
Endacof-C
Endacof-C, 2 mg-10 mg/5 mL oral liquid
EndaCof-DC
EndaCof-DC (codeine 10 MG / pseudoephedrine 30 MG) per 5 ML Oral Solution
EndaCof-DC, 10 mg-30 mg/5 mL oral liquid
EndaCof-DH
EndaCof-DH (brompheniramine 4 MG / dihydrocodeine 3 MG / phenylephrine 7.5 MG) per 5 ML Oral Solution
EndaCof-DH, 4 mg-3 mg-7.5 mg/5 mL oral liquid
EndaCof-DM
EndaCof-DM, 4 mg-30 mg-60 mg/5 mL oral syrup
EndaCof-PD
EndaCof-PD, 2 mg-5 mg-50 mg-5 mg/5 mL oral liquid
EndaCof-Plus
EndaCof-Plus (dexchlorpheniramine 2 MG / hydrocodone bitartrate 4 MG / phenylephrine 5 MG) per 5 ML Oral Solution
EndaCof-Plus, 2 mg-4 mg-5 mg/5 mL oral liquid
Endacon DM
Endacon DM, 30 mg-600 mg-20 mg oral tablet, extended release
Endacon-DM
Endacon-DM (dextromethorphan 30 MG / guaifenesin 600 MG / phenylephrine 20 MG) 12HR Extended Release Tablet
Endadenium
Endadenium gossweileri
Endafed
Endafed (brompheniramine 12 MG / pseudoephedrine 120 MG) 12 HR Extended Release Capsule
ENDAFED CAPSULES 12 MG/120 MG
Endafed, 12 mg-120 mg oral capsule, extended release
Endagen-HD
Endagen-HD (chlorpheniramine 2 MG / hydrocodone bitartrate 1.67 MG / phenylephrine 5 MG) per 5 ML Oral Solution
Endagen-HD, 2 mg-1.67 mg-5 mg/5 mL oral liquid
Endal
Endal (guaifenesin 300 MG / phenylephrine 20 MG) 12HR Extended Release Tablet
Endal CD
Endal CD (codeine 7.5 MG / diphenhydramine 7.5 MG / phenylephrine 12.5 MG) per 5 ML Syrup
Endal CD (codeine phosphate 7.5 MG / diphenhydramine 10 MG / phenylephrine 7.5 MG) per 5 ML Syrup
Endal CD, 7.5 mg-12.5 mg-7.5 mg/5 mL oral syrup
Endal Expectorant
Endal Expectorant, 10 mg-100 mg-12.5 mg/5 mL oral liquid
Endal HD
ENDAL HD PLUS
Endal HD Plus (chlorpheniramine 2 MG / hydrocodone bitartrate 2.5 MG / phenylephrine 5 MG) per 5 ML Oral Solution
Endal HD, 12.5 mg-2 mg-7.5 mg/5 mL oral syrup
Endal-HD
Endal-HD (chlorpheniramine 2 MG / hydrocodone bitartrate 1.67 MG / phenylephrine 5 MG) per 5 ML Oral Solution
Endal-HD (chlorpheniramine 2 MG / hydrocodone bitartrate 2 MG / phenylephrine 7.5 MG) per 5 ML Oral Solution
Endal-HD (diphenhydramine 12.5 MG / hydrocodone bitartrate 2 MG / phenylephrine 7.5 MG) per 5 ML Syrup, Reformulated Nov 2007
Endal-HD Plus
Endal-HD Plus, 2 mg-2.5 mg-5 mg/5 mL oral liquid
Endal-HD Reformulated Nov 2007
Endal-HD(obsolete)
Endal-HD(obsolete), 2 mg-1.67 mg-5 mg/5 mL oral liquid
Endal-HD(obsolete), 2 mg-2 mg-7.5 mg/5 mL oral liquid
Endal, 300 mg-20 mg oral tablet, extended release
endalin
Endamoeba histolytica
Endamoeba histolyticas
endanger
endangered
endangered animals
Endangered Species
endangering
endangerment
endangerments
endangers
Endantadine
ENDAP
endaround carry
Endarterectomies
Endarterectomies, Carotid
Endarterectomy
Endarterectomy Loop Drivers
Endarterectomy Loops
Endarterectomy NOS
Endarterectomy of abdominal arteries
Endarterectomy of aorta
Endarterectomy of femoral artery
Endarterectomy of intracranial vessels
Endarterectomy of lower limb arteries
Endarterectomy of other thoracic vessels
Endarterectomy of other vessels of head and neck
Endarterectomy of upper limb vessels
Endarterectomy Scissors
Endarterectomy with embolectomy
Endarterectomy with patch graft
Endarterectomy with temporary bypass during procedure
Endarterectomy with thrombectomy
Endarterectomy, Carotid
Endarterectomy, unspecified site
Endarterectomy; vessel of head and neck
Endarteritides
Endarteritis
Endarteritis [Disease/Finding]
Endarteritis NOS
Endaseina
Endasys
Endasys plagiator
Endasys sp. NL346
Endaural Scissors, Microsurgery
Endaural Surgery Burs
Endaural Surgery Curettes
Endaural Surgery Scissors
Endaural Wire Crimpers
EndB protein, Ruminococcus flavefaciens
endbell
endbrain
endcarriage
endcarriage bracing
endd2 protein, Drosophila
endeared
endearing
endearingly
endearment
endearments
endears
endeavor
endeavored
endeavorest
endeavoreth
endeavoring
endeavors
endeavour
endeavoured
endeavourest
endeavoureth
endeavouring
endeavours
endecaphyllacin A
endecaphyllacin B
Ended
Ended - status
ended off
ended up
ended-up bed
Endeidae
Endeis
Endeis australis
Endeis biseriata
Endeis laevis
Endeis mollis
Endeis nodosa
Endeis spinosa
endellionite
Endelomyia
Endelomyia aethiops
Endelomyia aethiops (Fabricius)
endemic
Endemic African Kaposi Sarcoma
Endemic African Kaposi's Sarcoma
Endemic Burkitt Lymphoma
Endemic Burkitt's Lymphoma
Endemic congenital iodine deficiency syndrome of myxedematous type
Endemic Cretinism
ENDEMIC DIS
Endemic Disease
Endemic Diseases
Endemic Flea-Borne Typhus
Endemic goiter
Endemic goiter or struma
Endemic Goiters
endemic infection
Endemic murine typhus
Endemic Nephropathy, Balkan
endemic plants
Endemic polyarthritis
endemic species
Endemic Typhus
Endemic Typhus fever
ENDEMIC TYROLEAN INFANTILE CIRRHOSIS
endemics
Endeostigmata
Endep
Endep 10 MG Oral Tablet
Endep 100 MG Oral Tablet
Endep 150 MG Oral Tablet
Endep 25 MG Oral Tablet
Endep 50 MG Oral Tablet
Endep 75 MG Oral Tablet
Endep, 10 mg oral tablet
Endep, 100 mg oral tablet
Endep, 150 mg oral tablet
Endep, 25 mg oral tablet
Endep, 50 mg oral tablet
Endep, 75 mg oral tablet
endergonic
endermic injection
Endermic medication
enderpin RP1
enderpin RP2
enderpin RP3
enderpins
Endertia
Endertia spectabilis
endest
ENDET
endeth
endevour
endevours
endexine
endgames
endgate
endgates
Endgerm
Endiandra
Endiandra impressicosta
Endiandra kingiana
Endiandra microneura
Endiandra pubens
endiandric acid
endiandrin A
endiandrin B
endiemal
Ending
ending in
ending off
ending up
Ending, Nerve
Ending, Presynaptic Nerve
endings
Endings, Nerve
Endings, Presynaptic Nerve
Endion
Enditussin Expectorant
Enditussin Expectorant, 10 mg-100 mg-12.5 mg/5 mL oral liquid
Enditussin-HD
Enditussin-HD (chlorpheniramine 2 MG / hydrocodone bitartrate 1.67 MG / phenylephrine 5 MG) per 5 ML Oral Solution
Enditussin-HD, 2 mg-1.67 mg-5 mg/5 mL oral liquid
endive
Endive (cichorium endivia) | bld-ser-plas
Endive (cichorium endivia) IgG | bld-ser-plas
Endive (dietary)
Endive IgE Ab [Units/volume] in Serum
Endive IgE Ab RAST class in Serum
Endive IgE Qn
Endive IgE RAST Ql
Endive IgG Ab [Units/volume] in Serum
Endive IgG Ab RAST class in Serum
Endive IgG Qn
Endive IgG RAST Ql
Endive necrotic mosaic virus
Endixaprine
endless
endless form
endless-tape
endlessly
endlessness
Endlicheria
Endlicheria anomala
Endlicheria bracteolata
Endlicheria chalisea
Endlicheria citriodora
Endlicheria dysodantha
Endlicheria formosa
Endlicheria gracilis
Endlicheria longicaudata
Endlicheria metallica
Endlicheria multiflora
Endlicheria paniculata
Endlicheria punctulata
Endlicheria pyriformis
Endlicheria reflectens
Endlicheria rubra
Endlicheria ruforamula
Endlicheria sp. 1 SMAma006
Endlicheria sp. 2 SMAma003
Endlicheria sprucei
Endlicheria tessmannii
Endlicheria verticillata
endline
endlos
endmills
endmost
endnote
Endo
Endo 1,3 beta Glucanase
Endo 1,3 beta Xylanase
Endo 1,4 beta Glucanase
Endo 1,4 beta Xylanase
Endo 1,4 beta Xylanase II
Endo 1,4 beta Xylanases
Endo 1,4 Xylanase II
endo 8-methyl-8-azabicyclo(3.2.1)octan-3-yl benzofurane-3-caboxylate
endo 8-methyl-8-azabicyclo(3.2.1)octan-3-yl benzofurane-3-carboxylate
Endo A Cytokeratin
Endo ak ultra-light material
Endo ak/hip alignable system
Endo ak/hip knee extens assi
endo alpha N Acetylgalactosaminidase
Endo B Cytokeratin
Endo below knee alignable sy
Endo beta Acetylglucosaminidase
Endo beta D Glucuronidase
ENDO BETA GLUCANASE 01 03
ENDO BETA GLUCANASE 01 03 04
ENDO BETA GLUCANASE 01 04
Endo beta N Acetylglucosaminidase D
Endo beta N Acetylglucosaminidase F
Endo beta N Acetylglucosaminidase H
ENDO BETA XYLANASE 01 03
ENDO BETA XYLANASE 01 04
ENDO BETA XYLANASES 01 04
endo beta-(1-5)-galactofuranase
Endo bk ultra-light material
Endo Brand of Amantadine Hydrochloride
Endo Brand of Molindone Hydrochloride
Endo Brand of Naloxone Hydrochloride
Endo brand of oxymorphine HCl
Endo Brand of Oxymorphone Hydrochloride
Endo D Endoglucosaminidase
Endo Dextranase
Endo em hd/nk,bioac coil
Endo emb hd/nk,bare coil
Endo F Endoglucosaminidase
ENDO GLUCANASE
Endo H Endoglucosaminidase
Endo hip ultra-light materia
Endo imp grft thor aorta
Endo impl grft abd aorta
Endo ins/re brnc val,mul
Endo ins/re bron val,one
Endo insrt bronc def/sub
Endo insrt colonic stent
Endo knee-shin fluid swg/sta
Endo knee-shin fluid swing p
Endo knee-shin frct swg & st
Endo knee-shin hydral swg ph
Endo knee-shin mnl lck ultra
Endo knee-shin pneum swg frc
Endo knee-shin pneum/swg pha
Endo knee-shin polyc mch sta
endo N
endo N Acetyl alpha D Galactosamidase
Endo N Acetyl beta d glucosaminidase
endo NE
endo NF
Endo Pharmaceuticals brand of lidocaine
Endo polpectomy lrge int
Endo pulm arwy flow msmt
Endo R
Endo rem bronch devc/sub
Endo rem obs hd/neck ves
Endo robotic assist proc
Endo transmyo revascular
endo V
endo X3
Endo X3 activity
endo-
endo-(+/-)-alpha-(Hydroxymethyl)benzeneacetic Acid 8-methyl-8-azabicyclo[3.2.1]oct-3-yl Ester
endo-(1->2)-beta-D-glucanase activity
endo-(1->3)-alpha-glucanase activity
endo-(1->3)-beta-D-glucanase activity
endo-(1->4)-beta-xylanase(1->4)-beta-xylan 4-xylanohydrolase activity
endo-(1->6)-beta-D-glucanase activity
endo-(1-5)-alpha-L-arabinanase
endo-(1,3)-beta-D-glucanase activity
endo-(1,6)-beta-D-glucanase activity
endo-(8-methyl-8-aza-bicyclo(3.2.1)oct-3-yl)-1-isobutyl-2-oxo-1,2-dihydro-4-quinolinecarboxylate hydrochloride
ENDO-1
Endo-1 protein, Ciona savignyi
endo-1-6-D-mannanase
endo-1,2-beta-glucanase activity
endo-1,3-(4)-beta-D-glucanase
endo-1,3-1,4-beta-D-glucanase
endo-1,3-1,4-beta-D-glucanase activity
endo-1,3-1,4-D-glucanase
endo-1,3-alpha-D-glucanase
endo-1,3-alpha-D-glucanase activity
65 66 67 68 69